CAS 13721-39-6|Sodium orthovanadate
| Common Name | Sodium orthovanadate | ||
|---|---|---|---|
| CAS Number | 13721-39-6 | Molecular Weight | 183.908 |
| Density | / | Boiling Point | / |
| Molecular Formula | Na3O4V | Melting Point | 850-866 °C(lit.) |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | trisodium vanadate |
|---|---|
| Synonym | More Synonyms |
Sodium orthovanadate BiologicalActivity
| Description | Sodium orthovanadate is an inhibitor of protein tyrosine phosphatases, alkaline phosphatases and a number of ATPases, most likely acting as a phosphate analogue. |
|---|---|
| Related Catalog | Signaling Pathways >>Metabolic Enzyme/Protease >>PhosphataseBiochemical Assay ReagentsResearch Areas >>Cancer |
| Target | PPTPase[1]. |
| In Vitro | In the presence of oxidizing agents vanadium ions exist as the hydrated monomer of Sodium orthovanadate (vanadate: HVO42- or H2VO4-) at micromolar concentations near neutral pH. Sodium orthovanadate (vanadate) also begins to polymerize at concentrations greater than 0.1 mM at neutral pH. The yellow-orange solutions of decavanadate can be converted to the colorless solutions of monomeric Sodium orthovanadate (vanadate) by dilution after a period of many hours. The process is hastened by boiling at pH 10, which encourages the kinetically sluggish depolymerization process[1]. Sodium orthovanadate could alter the phosphorylation status of ASK1 at serine 83 and threonine 845 induced by ischemia. Sodium orthovanadate could increase the tyrosine posphorylation of PTEN and further inhibit the activation of ASK1 via activating Akt during cerebral ischemia[2]. |
| References | [1]. Gordon JA, et al. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 1991;201:477-82. [2]. Wu DN, et al. Down-regulation of PTEN by sodium orthovanadate inhibits ASK1 activation via PI3-K/Akt during cerebral ischemia in rat hippocampus. Neurosci Lett. 2006 Aug 14;404(1-2):98-102. |
Chemical & Physical Properties
| Melting Point | 850-866 °C(lit.) |
|---|---|
| Molecular Formula | Na3O4V |
| Molecular Weight | 183.908 |
| Exact Mass | 183.892929 |
| PSA | 86.25000 |
| InChIKey | IHIXIJGXTJIKRB-UHFFFAOYSA-N |
| SMILES | O=[V]([O-])([O-])[O-].[Na+].[Na+].[Na+] |
| Storage condition | Store at RT |
| Stability | Stable. Incompatible with strong oxidizing agents. |
| Water Solubility | soluble |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 330 mg/kg
- TOXIC EFFECTS :
- Gastrointestinal - hypermotility, diarrhea Blood - hemorrhage
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 36300 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 50 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 100 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 9280 ug/kg
- TOXIC EFFECTS :
- Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea Blood - hemorrhage
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - guinea pig
- DOSE/DURATION :
- 1 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 5054 mg/kg/10W-I
- TOXIC EFFECTS :
- Behavioral - excitement Gastrointestinal - ulceration or bleeding from small intestine Related to Chronic Data - death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 33750 ug/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 300 mg/kg
- SEX/DURATION :
- female 6-15 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- Micronucleus test
- TYPE OF TEST :
- Cytogenetic analysis
- TYPE OF TEST :
- Sex chromosome loss and nondisjunction
MUTATION DATA - TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Mammal - species unspecified Kidney
- REFERENCE :
- JCLBA3 Journal of Cell Biology. (Rockefeller Univ. Press, 1230 York Ave., New York, NY 10003) V.12- 1962- Volume(issue)/page/year: 79,573,1978 *** REVIEWS *** TOXICOLOGY REVIEW FRMBAZ Farmacia (Bucharest). (Rompresfilatelia, POB 12-201, Bucharest, Romania) V.1- 1953- Volume(issue)/page/year: 21,325,1973 TOXICOLOGY REVIEW 85DHAX "Medical and Biologic Effects of Environmental Pollutants Series," Washington, DC, National Academy of Sciences, 1972-77 Volume(issue)/page/year: V,46,1974 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-AUSTRALIA:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-BELGIUM:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-DENMARK:TWA 0.03 mg(V2O5)/m3 JAN 1993 OEL-FINLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-FRANCE:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-GERMANY:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-HUNGARY:TWA 0.05 mg(V2O5)/m3;STEL 0.1 mg(V205)/m3 JAN 1993 OEL-JAPAN:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE NETHERLANDS:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.25 mg(V205)/m3 JAN 1993 OEL-POLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:STEL 0.05 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:TWA 0.2 mg(V2O5)/m3 (dust) JAN 1993 OEL-SWITZERLAND:TWA 0.05 mg(V2O5)/m3;STEL 0.25 mg(V2O5)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.05 mg(V2O5)/m3 (dust) JAN 1993 OEL-UNITED KINGDOM:TWA 0.5 mg(V2O5)/m3 JAN 1993 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO VANADIUM (as V2O5), resp dust/fume-air:CL 0.05 mg/m3/15M REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992
- TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Mammal - species unspecified Kidney
- REFERENCE :
- JCLBA3 Journal of Cell Biology. (Rockefeller Univ. Press, 1230 York Ave., New York, NY 10003) V.12- 1962- Volume(issue)/page/year: 79,573,1978 *** REVIEWS *** TOXICOLOGY REVIEW FRMBAZ Farmacia (Bucharest). (Rompresfilatelia, POB 12-201, Bucharest, Romania) V.1- 1953- Volume(issue)/page/year: 21,325,1973 TOXICOLOGY REVIEW 85DHAX "Medical and Biologic Effects of Environmental Pollutants Series," Washington, DC, National Academy of Sciences, 1972-77 Volume(issue)/page/year: V,46,1974 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-AUSTRALIA:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-BELGIUM:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-DENMARK:TWA 0.03 mg(V2O5)/m3 JAN 1993 OEL-FINLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-FRANCE:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-GERMANY:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-HUNGARY:TWA 0.05 mg(V2O5)/m3;STEL 0.1 mg(V205)/m3 JAN 1993 OEL-JAPAN:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE NETHERLANDS:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.25 mg(V205)/m3 JAN 1993 OEL-POLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:STEL 0.05 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:TWA 0.2 mg(V2O5)/m3 (dust) JAN 1993 OEL-SWITZERLAND:TWA 0.05 mg(V2O5)/m3;STEL 0.25 mg(V2O5)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.05 mg(V2O5)/m3 (dust) JAN 1993 OEL-UNITED KINGDOM:TWA 0.5 mg(V2O5)/m3 JAN 1993 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO VANADIUM (as V2O5), resp dust/fume-air:CL 0.05 mg/m3/15M REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 + H312 + H332 |
| Precautionary Statements | P280 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn:Harmful; |
| Risk Phrases | R20/21/22 |
| Safety Phrases | S22-S36 |
| RIDADR | UN3285 |
| WGK Germany | 3 |
| RTECS | YW1120000 |
| Packaging Group | III |
| Hazard Class | 6.1 |
Articles575
More Articles| A survey of the interactome of Kaposi's sarcoma-associated herpesvirus ORF45 revealed its binding to viral ORF33 and cellular USP7, resulting in stabilization of ORF33 that is required for production of progeny viruses. J. Virol. 89(9) , 4918-31, (2015) The ORF45 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is a gammaherpesvirus-specific immediate-early tegument protein. Our previous studies have revealed its crucial roles in both early ... | |
| Progressive accumulation of activated ERK2 within highly stable ORF45-containing nuclear complexes promotes lytic gammaherpesvirus infection. PLoS Pathog. 10(4) , e1004066, (2014) De novo infection with the gammaherpesvirus Rhesus monkey rhadinovirus (RRV), a close homolog of the human oncogenic pathogen, Kaposi's sarcoma-associated herpesvirus (KSHV), led to persistent activat... | |
| Disturbed Hsp70 and Hsp27 expression and thiol redox status in porcine kidney PK15 cells provoked by individual and combined ochratoxin A and citrinin treatments. Food Chem. Toxicol. 71 , 97-105, (2014) The aim of this study was to explore the oxidative properties of ochratoxin A (OTA) and citrinin (CTN) as a possible underlying mechanism of their individual and/or combined cytotoxicity. Metabolic ac... |
Synonyms
| Trisodium tetraoxovanadate(3-) |
| Vanadate(3-), tetraoxo-, sodium (1:3) |
| sodium tetraoxovanadate(3-) |
| MFCD00003511 |
| Sodium orthovanadate |
| EINECS 237-287-9 |
